Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.
Incyte today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 ...
The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...
Primary central nervous system T-cell lymphoma (PCNS-TCL) is an exceptionally rare entity, representing less than 5% of all PCNSLs. Its diagnosis is frequently delayed due to nonspecific radiologic ...
Abstract: Accurate survival prediction using multimodal magnetic resonance imaging (MRI) plays a crucial role in clinical decision-making for patients with glioblastoma (GBM). In this work, we propose ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Robert Brams writes about his battle with brain cancer in the new book, "Forever Optimistic." Brams joined CBS News to talk about the book and his journey. Trump signs executive order reclassifying ...
Israeli researchers at a blood cancer conference in the US reported a lymphoma treatment that can achieve 100% survival rates. The results, compiled across 15 medical centers, revealed that patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback